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 Environmental pollutant exposure has gained considerable attention as a potential 
risk factor contributing towards cardiovascular diseases (CVDs). Acrolein is a highly 
reactive electrophilic aldehyde known for its ubiquitous presence in the atmosphere. It is 
generated during the burning of organic matter and fuels and gets released into the 
atmosphere through smoke. Acrolein has been studied in the pathology of various 
respiratory and neurodegenerative disorders. However, the mechanisms regulating the 
cardiovascular risk implications of acrolein have not been understood completely. The 
goal of this project was to investigate acrolein-induced cell injury and endothelial 
dysfunction.  
 Acrolein, at lower concentrations of 20 and 40 µM, was shown to cause no effect 
in cellular viability. However, these concentrations of acrolein significantly increased 
monocyte-endothelial binding through increased expression of monocyte chemoattractant 
protein-1 (MCP-1), E-selectin, and Interleukin (IL)-8. In addition, acrolein also depleted 
cellular and mitochondrial glutathione (GSH) and increased the levels of reactive oxygen 
species (ROS) in endothelial cells. Furthermore, acrolein also induced nuclear factor-
kappa B (Nf-kB) transcriptional activity, degradation of inhibitor of kappa B (IkB-α), and 
nuclear translocation of the p65 subunit.
In contrast, acrolein, at higher concentrations of 80 and 120 µM, was shown to 
promote EA.hy926 endothelial cell death. In addition, acrolein-incurred cell death at 
those concentrations was classified to be necrosis, as evidenced by the increased release 
of lactose dehydrogenase (LDH) and increased staining of DNA-binding propidium 
iodide (PI). Acrolein also rapidly depleted cellular antioxidant glutathione (GSH) and 
phase II detoxification enzymes, glutathione-S-transferase (GST) and NAD(P)H Quinone 
Oxireductase-1 (NQO1), in a dose-dependent manner. To further determine the role of 
GSH in acrolein-mediated cytotoxicity, we pretreated the cells with buthionine 
sulfoximine (BSO), an inhibitor for cellular GSH biosynthesis. It was observed that 
depleted GSH levels significantly potentiated acrolein toxicity. Next, induction of cellular 
GSH levels, achieved through pre-treatment of endothelial cells with CDDO-Im (1-[2-
cyano-3,12 dioxooleana -1,9(11)- dien-28-oyl] imidazolide), was shown to offer 
cytoprotection against acrolein toxicity. It was also found that the upregulation of GSH 
by CDDO-Im involved the activation of the Nrf2/ARE signaling and increased 
expression of the modifier-subunit of γ-glumatylcysteine ligase (GCLM). 
In conclusion, acrolein at low concentrations induces monocyte-endothelial 
interactions, a key step in early atherosclerosis, through depletion of intracellular GSH 
and activation of Nf-kB pathway. Acrolein at high concentrations induces necrosis in 
endothelial cells, which can enhance the inflammatory response and increase the 
susceptibility of developing atherosclerosis. Upregulation of GSH can provide protection 
against acrolein-mediated cell death. The results, taken together, provide evidence for the
cardiovascular risk posed by acrolein and the importance of GSH and Nf-kB in acrolein 
toxicity.  
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CHAPTER I 
BACKGROUND 
 
 
Atherosclerosis 
Cardiovascular diseases (CVDs) account for the highest mortality rate for both, 
men and women, in the United States. Each year, approximately 1.5 million American 
adults have a heart attack or stroke [1]. In 2010 alone, CVDs accounted for 31.9% of all 
deaths, or about 1 in every 3 deaths [2]. Most of these CVDs are understood to initiate 
through a pathological state called atherosclerosis. Atherosclerosis is the build-up of 
plaques within the arterial walls, narrowing the arterial lumen, and restricting the amount 
of blood that flows through it. The plaques, formed between the tunica intima and tunica 
media, are comprised of an accumulation of lipids, cells, debris, and fibrous tissues [3]. 
In severe cases, the plaques become vulnerable and rupture, attracting coagulant factors 
in the blood towards the rupture site [3]. With limited blood flow through these clogged 
arteries, atherosclerosis leads to major complications like heart attack, strokes, and 
aneurysm [3]. 
Extensive studies have confirmed that atherosclerosis initiates with endothelial 
dysfunction.  Endothelial cells lineup the inner arterial wall and are essential in 
maintaining vascular homeostasis, platelet activity, leukocyte adhesion, permeability, and 
innate immunity [4]. Under the influence of various factors, endothelial cells become 
activated, making them dysfunctional, which can be characterized with the expression of
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adhesion molecules, binding of blood monocytes, and increased permeability and 
accumulation of circulating lipids [5]. Previous studies have showed that leukocyte 
binding, facilitated by adhesion molecules and chemokines, is a key step in the 
development of atherosclerosis [4, 6-9].  The normal endothelial monolayer resists 
prolonged contact and adhesion to circulating blood monocytes. However, when 
endothelial cells undergo inflammatory activation, they increase the expression of 
leukocyte adhesion molecules [10]. Various pro-inflammatory mediators and cell 
adhesion molecules have been found to be secreted by injured endothelial cells, which 
include thrombin, tumor necrosis factor-alpha (TNF-α), monocyte chemoattractant 
protein-1 (MCP-1), Interleukin-8 (IL-8), E-selectin, vascular cell adhesion molecule-1 
(VCAM-1), and intracellular adhesion molecule-1 (ICAM-1) [6-9]. Increased production 
of these cytokines serves as a molecular marker for endothelial inflammation. The 
adhesion molecules facilitate the recruitment of blood monocytes from the circulation to 
the endothelium followed by transmigration of the leukocytes to the sub-endothelial [5, 
10, 11]. Furthermore, when blood monocytes migrate to the innermost layer of the 
arterial wall, they differentiate to macrophage foam cells accumulating lipids and 
lipoprotein particles [10]. These foam cells secrete large amount of TNF-α and other 
cytokines such as IL-8, E-selectin, which in turn amplify the inflammatory response and 
enhance vascular complications [10, 11]. 
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Air Pollution-CVD Risk Factor 
Many risk factors such as aging, hypercholesterolemia, hyperglycemia, 
hypertension, and environmental factors have been associated progressively with 
atherosclerotic development [4]. Among the various environmental factors, air pollution 
has been gaining a lot of attention as a potential risk factor contributing towards CVDs. 
Recently, epidemiological studies have demonstrated the association between exposure to 
air pollution and the risk of developing CVDs [12, 13]. The cardiovascular manifestations 
resulting from exposure to air pollutants include accelerated atherosclerosis, 
hypertension, myocardial infarction, and heart failure [14-20]. A few longitudinal studies, 
involving human subjects, have looked into the association between air pollutants and 
CVDs. Using thousands of human subjects with no previous record of CVDs, Adar et al. 
(2013) demonstrated that higher, long-term exposure to particulate matter in air pollution 
was associated with increased intima-medial thickness (IMT) of the common carotid 
arteries, an indicator of atherosclerotic progression [21]. Also, numerous animal studies 
have demonstrated the crucial involvement of air pollutants and particulate matter in 
atherosclerotic development. For example, exposure to air pollution particulate matter 
was found to increase the formation and vulnerability of atherosclerotic plaques in rabbits 
[22, 23]. Although, air pollution has been recognized as an important contributor towards 
CVDs in humans, its underlying mechanisms remain unclear. 
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Acrolein: A Common Component of Air Pollution  
Acrolein, a highly reactive aldehyde species, is a major air pollutant. It is a pale-
yellowish or clear liquid with an acrid, pungent odor [24]. The odor threshold for acrolein 
is between 0.1 - 0.25 parts acrolein per million parts of air (ppm) [25]. The high vapor 
pressure of acrolein makes it readily volatile. It can change from liquid to vapor at a 
faster rate than water at normal temperatures, and its volatility increases with increasing 
temperatures [24]. It is also highly soluble in water. Therefore, acrolein can be found in 
air, water, and soil. Commercially, acrolein is used in the production of other chemicals, 
including acrylic acid. It is also used in pesticides, herbicides, and may also be found in 
some livestock feed. 
Humans are exposed to acrolein every day, particularly through inhalation of 
smoke, including cigarette smoke. Fujioka and Shibamoto (2006) have reported about 
200-500 µg of acrolein per cigarette [26]. Environmental acrolein (about 1/3rd the amount 
found in cigarettes) corresponds to a wider array of exposure [27]. Acrolein gets released 
into the atmosphere through incomplete combustion of organic matter like trees and 
plants and also through burning of fuels like gasoline and diesel. So it is found in all 
kinds of smoke including cigarette smoke, automobile exhaust, smoke from power plants, 
furnaces, and fireplaces and even burning foods and oils [25, 27, 28]. With urbanization 
and increase in air pollution, humans, today, are continuously exposed to acrolein. The 
US Environmental Protection Agency (EPA) estimates that over 60,000 metric tons of 
acrolein is emitted annually in the US [24, 27]. Because of its ubiquitous presence, the 
EPA has classified acrolein as a high-priority air and water toxin [28]. 
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Acrolein has been known to initiate and be a byproduct of lipid peroxidation [28]. 
Interestingly, it is also produced endogenously in our bodies through the oxidation of 
lipids and proteins. In that regards, a large body of research has investigated the role of 
acrolein in the pathogenesis of various neurodegenerative diseases including Alzheimer’s 
disease. Lipid peroxidation in neuronal cells can generate large quantities of acrolein that 
conjugates with cellular proteins and DNA to form adducts [29, 30]. In addition, the route 
of human exposure to acrolein, primarily through inhalation, has instigated research 
focused on implementation of respiratory disease conditions. However, the impact of 
acrolein on endothelial cells and its role in the development of atherosclerosis has not 
been well studied. Increased acrolein levels have been reported in atherosclerotic lesions 
[31], but the mechanism through which acrolein contributes towards atherosclerotic 
development is not known. 
 
Proposed Study 
 The primary goal of this proposal is to investigate the role and underlying 
mechanisms of acrolein in regulation of vascular endothelial dysfunction. We 
hypothesized that depletion of glutathione (GSH) by exposure to acrolein will increase 
expression of adhesion molecules and the subsequent endothelial dysfunction, and 
augmentation of intracellular GSH will ameliorate acrolein-induced toxicity in 
endothelial cells. Accordingly, the study aims were designed to 1) examine the induction 
of monocyte adherence to endothelial cells following acrolein treatment and its 
6 
 
underlying mechanisms and 2) examine acrolein-induced endothelial cell death and 
whether intracellular GSH supplementation could protect against this damage.
7 
 
CHAPTER II 
MECHANISMS OF ACROLEIN-INDUCED MONOCYTE ADHERENCE 
 
 
Abstract 
 Acrolein is an unsaturated aldehyde that is predominantly found in smoke and air 
pollution. It is one of the major toxicants associated with severe health concerns. In this 
study, we investigated the implications of acrolein in early atherogenesis by examining 
monocyte adherence to endothelial cells; the mechanisms underlying this atherogenic 
defining step were also studied. Our results show that acrolein, at concentrations as low 
as 10 µM, significantly induced monocyte binding to EA.hy926 endothelial cells through 
increased expression of MCP-1, E-selectin, and IL-8. Acrolein also depleted cellular and 
mitochondrial GSH and increased the generation of ROS in endothelial cells. Finally, 
acrolein upregulated the transcriptional activity of genes modulated by βB through 
degradation of the Nf-kB inhibitor, IkB-α, and increased nuclear translocation of the p65 
subunit. These results provide evidence that acrolein augments monocyte binding to 
endothelial cells, possibly through the Nf-kB pathway.  
 
Introduction 
 Atherosclerosis is a progressive chronic condition that involves the build-up of 
plaques within the arterial walls and results in the hardening and narrowing of the 
arteries. It leads to major complications like myocardial infarction, cerebral infarction,
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and aortic aneurysm [5] and has been accounted for over 24% of total deaths in the 
United States [2]. Numerous studies have indicated that atherosclerosis is a complex, 
multi-step process and is preceded by endothelial dysfunction [3, 5, 32]. Under the 
influence of various factors, endothelial cells become activated and impaired resulting in 
inflammation, increased permeability, vascular lesion, and thrombosis [5, 32]. A key 
hallmark of atherosclerotic development is the interaction and subsequent binding of the 
blood monocytes to inflamed endothelium [3, 33]. Various chemotactic cytokines like 
interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and other leukocyte 
adhesion molecules like vascular cell adhesion molecule-1 (VCAM-1), intercellular 
adhesion molecule-1(ICAM-1), and E-selectin facilitate with the firm adhesion of 
monocytes to endothelial cells. Pro-atherogenic risk factors like oxidized-low density 
lipoproteins (ox-LDL), fatty acids, tumor necrosis factor-alpha (TNF-α), and angiotensin 
II have been shown to increase monocyte adherence to endothelium through increased 
expression of these molecules [11, 34-36]. Higher levels of plasma E-selectin, ICAM-1, 
and VCAM-1 have also been observed in patients with carotid atherosclerosis and 
coronary heart diseases compared to control subjects [37]. Once adhered to inflamed sites 
on the arteries, monocytes transmigrate to the sub-endothelial space, where they engulf 
accumulating lipids and oxidized-lipoprotein particles, differentiate, and undergo 
apoptosis to give rise to the lipid-rich core of atherosclerotic plaques [10, 11].  
Epidemiological studies have demonstrated association between exposure to air 
pollution and the risk of developing cardiovascular diseases (CVDs) [12, 13]. In vitro 
studies have also demonstrated that airborne particulate matter, consisting of transition 
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metals, hydrocarbons, and endotoxins, causes cytotoxicity via oxidative stress [38]. 
Mixture of several chemicals and toxicants from air pollution particulate matter have also 
been shown to induce cardiovascular injury and disease progression [22, 23], however 
specific chemicals that accelerate CVD risk have not been identified. Acrolein, a highly 
reactive aldehyde, is a major air pollutant. Inhalation of smoke, including cigarette 
smoke, automobile exhaust, and pollution, is the primary route of human exposure to 
acrolein. Because of its high reactivity, it is challenging to measure accurate 
concentrations of acrolein in the atmosphere. Studies have reported less than a few 
micromolar concentration of acrolein in ambient air [27, 39]. However, in an enclosed 
setting such as homes, restaurants, and bars, acrolein concentrations can rise up to 20 
times the environmental concentration [27]. In addition to its ubiquitous-natured 
exposure, endogenous generation has resulted in higher concentrations of acrolein 
aggregated in human tissues and serum. Acrolein concentrations have been reported to be 
as high as 80 µM in respiratory fluid of smokers and over 180 µM in patients with renal 
failure [39]. Acrolein adduction has been found to interrupt and alter the regular function 
of cellular macromolecules and biomolecules, resulting in cellular damage and death [40, 
41]. It has also been implicated in pathological conditions involving oxidative stress 
including neurodegenerative and pulmonary disorders [39, 42]. However, the 
cardiovascular implications of acrolein have not been studied extensively. 
Since monocyte binding is a key aspect of atherosclerotic development, we tested 
the hypothesis that acrolein exposure activates and recruits monocytes to endothelial 
cells. We found that acrolein promoted the adhesion of THP-1monocytes to EA.hy926 
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endothelial cell monolayer by increasing the expression of various adhesion molecules 
and chemokines, including E-selectin, MCP-1, and IL-8. We also found that the increased 
expression of these adhesion molecules was regulated by nuclear factor kappa B (Nf-kB) 
activation and increased levels of reactive oxygen species (ROS). 
 
Materials and Methods 
 
     Chemicals  
Acrolein (≥95%, GC) was from Sigma chemicals (St. Louis, MO). Dulbecco’s 
Modified Eagle Medium (DMEM), Fetal Bovine Serum (FBS), and Penicillin 
Streptomycin (Penn Strep) were from Gibco-Invitrogen (Carlsbad, CA). Calcein-AM and 
SYBR® Green Master Mix were from Life Technologies (Grand Island, NY). 
Oligonucleotide primers were from Eurofins (Huntsville, AL). Recombinant human 
TNF-α was from PeproTech (Rockyhill, NJ). TGX™ precast gels and western blot 
buffers were from Bio-Rad (Hercules, CA). IkB-α, p65 primary antibodies were from 
Santa Cruz Biotechnology (Santa Cruz, CA) and GAPDH primary antibody was from 
Cell Signaling Technology Inc. (Danvers, MA) respectively. The FuGENE® HD 
Transfection Reagent and Dual-Glo® Luciferase Assay System were from Promega 
(Madison, WI). All other general chemicals were from Sigma-Aldrich (St. Louis, MO).  
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     Cell Culture and Treatment  
EA.hy926 endothelial cells were grown in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 1% Penicillin 
Streptomycin (Penn Strep) in cell culture treated flasks at 37°C with 5% CO2 in a 
humidified incubator. The culture media was replaced every 2-3 days and cells were 
passaged around 90% confluence. For acrolein treatment, the cells were grown in cell 
culture treated petri-dishes under the same conditions. Acrolein was diluted in Medium 
199 (M199) supplemented with 2% FBS and 1% Penn Strep. The DMEM media was 
replaced with the acrolein-diluted M199 media and incubated for different time periods 
based on the specific assays.   
 
     ViaCount Assay 
EA.hy926 cells were grown to confluence and treated with acrolein for 24 hours. 
The cells were harvested through trypsinization and resuspended in PBS. The cells were 
then mixed with Guava ViaCount Reagent and incubated in the dark for 15 minutes. The 
stained cell samples were analyzed using the Guava easyCyte™ flow cytometer and cell 
viability for the treatment groups were expressed relative to an untreated control. 
 
     Adhesion Assay 
EA.hy926 cells were grown to confluence, followed by acrolein treatment for 6 
hours. The cells were washed with serum-free media and calcein-labeled monocytes were 
added to the cells. Following an hour of incubation, the cells were washed gently with 
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PBS to remove unbound monocytes. Finally, the fluorescence intensity was measured 
using the Bio-Tek microplate reader at excitation and emission wavelengths of 496 nm 
and 520 nm respectively to determine the quantity of bound monocytes as compared to 
the untreated control. 
 
     Quantitative Polymerase Chain Reaction (qRT-PCR)  
EA.hy926 cells were grown to confluence and exposed to acrolein for 3 hours. 
Total RNA from the cells was extracted using the Trizol Reagent. The purity and quantity 
of the isolated RNA were assessed using the Nanodrop spectrophotometer. The isolated 
RNA was then reverse transcribed to cDNA. One µl of the amplified cDNA was added to 
the SYBR® Green real-time PCR master mix along with specific primer sets. The 
specific primers for E-selectin were forward 5'-AGCCCAGAGCCTTCAGTGTA-3' and 
reverse 5'-AACTGGGATTTGCTGTGTCC-3', IL-8 were forward 5'-
TAGCAAAATTGAGGCCAAGG-3' and reverse 5'-AAACCAAGGCACAGTGGAAC-
3', MCP-1 were forward 5'-GCTCAGCCAGATGCAATCAA-3' and reverse 5'-
GGTTGTGGAGTGAGTGTTCAAG-3', and GAPDH were forward 5'-
CGACCACTTTGTCAAGCTCA-3' and reverse 5'-AGGGGTCTACATGGCAACTG-3'. 
The reaction cycles were performed in the Applied Biosystems thermal cycler. A total of 
40 cycles was performed for each run as following: 95ºC for 15 seconds, 61ºC for 30 
seconds, and 72ºC for 30 seconds. Expression of the housekeeping gene, GAPDH, was 
also acquired to normalize the expression of other target genes. Quantification of gene 
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expression was determined using the comparative threshold cycle CT method and 
expressed as fold-change compared to the untreated control.   
 
     ROS Detection Assay  
Reactive oxygen species (ROS) were detected using the luminol-dependent-
chemiluminescence assay. EA.hy926 cells were harvested and suspended in air saturated 
complete phosphate buffered saline (cPBS) solution. Aliquots of 5X105 cells, in 
microcentrifuge tubes, were added with 5 µl of luminol, 5 µl of horseradish peroxidase 
(HRP), and acrolein. The cell suspension was mixed thoroughly by vortexing and was 
transferred immediately into white 96-well assay plates. Luminescence intensity of 
luminol catalyzed by HRP and amplified by ROS was measured in Bio-Tek microplate 
reader for 30 minutes at 24 second intervals. Integrated chemiluminescence of the various 
acrolein treatments were expressed as fold-change compared to an untreated control. 
 
     Sample Preparation 
After acrolein treatment, the treatment media was dumped and the cells were 
washed with Phosphate Buffered Saline (PBS) twice. The cells were trypsinized with the 
addition of about 4 mL of trypsin, followed by incubation at 37°C for 3 minutes and 
collected through centrifugation. The pellet was resuspended in PBS to wash off trypsin 
and media remnants. The cells were centrifuged again and the pellet was resuspended in 
250 µL of sterile tissue lysis buffer. Next, the cells were sonicated 3 times for 15 seconds 
with a 15 second interval after each sonication. The sonicated cell lysate was centrifuged 
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again and the supernatant was collected in a new microcentrifuge tube and was used to 
perform the various antioxidant enzyme assays.  
 
     Mitochondrial Extract Preparation 
EA.hy926 cells were grown to confluence, followed by acrolein exposure for 24 
hours. The cells were harvested through trypsinization, and the pellet was resuspended in 
Sucrose Buffer (0.25M sucrose, 10mM Hepes, 1mM EDTA) at pH 7.4 with 0.1% BSA. 
The cell solution was homogenized using a Dounce homogenizer, followed by 
centrifugation at 1,000 x g for 10 minutes. The supernatant, containing the mitochondrial 
fraction, was collected in a fresh microcentrifuge tube and was centrifuged again at 
10,000 x g for 10 minutes. The mitochondrial pellet was resuspended in 250 µL of 
sucrose buffer without BSA and was sonicated 3 times for 15 seconds with 15 second 
intervals after each sonication. Finally, total protein and GSH concentration was 
measured for the mitochondrial lysate.   
 
     Glutathione (GSH) Assay 
Cellular and mitochondrial GSH was determined by o-phthalaldehyde (OPT) 
fluorometric method. EA.hy926 cells, grown to confluence, were exposed to various 
acrolein concentrations for 24 hours. Ten microliters of the collected cell lysate were 
incubated with 12.5 µl of 25% meta-phosphoric acid and 0.1% sodium phosphate buffer 
at pH 8.0 for 10 minutes at 4º C. The sample was centrifuged at 13,000 rpm for 5 
minutes, and 10 µl of the resulting supernatant was further incubated with 0.1% OPT in 
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methanol  and 0.1% sodium phosphate buffer for 15 minutes at room temperature in the 
absence of light. Fluorescence intensity of GSH-OPT was measured by excitation at 350 
nm and emission at 420 nm. The sample GSH content was calculated using a GSH 
standard curve and was expressed as percentage compared to an untreated control. 
 
     Nuclear Extract Preparation  
Once treated with acrolein, the cells were collected through trypsinization and 
nuclear proteins were isolated using the EpiQuik Nuclear Extraction Kit as per the 
manufacturer’s protocol. The cytoplasmic protein fraction was also collected for 
downstream applications.    
 
     Total Protein Assay  
Ten µL of the sample was diluted in 790 µL of deionized water and 200 µL of 
Bradford Protein Dye was added to bring the final volume to 1 ml. The solution was 
mixed thoroughly and sample absorbance at 595 nm was measured to determine the total 
protein concentration based on the absorbance of a Bovine Serum Albumin (BSA) 
standard, 1.48 mg/ml. 
 
     Western Blot  
Total protein concentration of the collected samples was initially measured. The 
nuclear and cytoplasmic extract for all acrolein treatments were diluted to an equal 
concentration in Laemmli buffer containing β-mercaptoethanol, heated at 95°C for 5 
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minutes, and loaded into TGX™ precast gels. After running the gels, the separated 
proteins were transferred to a nitrocellulose membrane using the Bio-Rad transfer buffer 
at 80 volts for 2.5 hours. The transfer setup was put in an ice-cold environment to counter 
the heat produced during the transfer process. The membrane was then blocked in 1% 
BSA supplemented Tris-buffered saline with 0.05% Tween-20 (TBST) for an hour. The 
two blotted membrane, containing the nuclear and cytoplasmic proteins each, were 
incubated with anti-p65 and anti-IkB-α in TBST overnight at 4°C respectively. Unbound 
antibodies were washed off and the membrane was then probed with horseradish 
peroxidase-conjugated secondary antibody for an additional hour. The blot was then 
developed in Super Signal West Pico Chemiluminescent Substrate and protein bands 
were developed in the Bio-Rad ChemiDoc XRS System. The membrane was then 
incubated with stripping buffer at 37 ºC for 20 minutes. The membrane was washed with 
TBST several times and blocked again in 1% BSA supplemented TBST for an additional 
hour. Finally, the membrane was probed again with anti-GAPDH primary antibodies, and 
GAPDH protein levels served as loading controls.    
 
     Transfection Assay  
EA.hy926 cells, grown to about 60% confluence, were cotransfected with 2 µg of 
Nf-kB-promoter-luciferase reporter vectors and Renilla luciferase control vector using 
the FuGENE® HD Transfection Reagent following the manufacturer’s protocol. 
Following incubation with the vectors for 24 hours, the cells were treated with 40 µM 
acrolein for 3 and 6 hours in presence of the transfection media. The transfected cells 
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were washed with PBS two times and then lysed in a reporter lysis buffer. The lysate 
solution was repeatedly pipetted to ensure complete lysis of the cells. Firefly 
luminescence from the reporter vector and renilla luminescence from the control vector 
were measured in a luminometer using the Dual-Glo® Luciferase Assay Systems 
following the manufacturer’s protocol. The renilla luminescence served as a transfection 
control and was used to normalize the expression of the Nf-kB reporter vector.  
 
Results 
 
     Acrolein-Induced Endothelial Cell Death 
We, first, investigated the effect of acrolein on endothelial cell viability. 
EA.hy926 cells were treated with various concentrations of 20, 40, 80, and 120 µM 
acrolein for 24 hours and cellular viability was measured by a ViaCount assay. ViaCount 
dye-stained cells that fall on the right-side of the slanted gate represent dead cells, while 
cells that fall on the left-side represent viable cells. With all acrolein treatments, there is 
an increase in the number of cells plotted on the right-side of the gate (Fig. 1B). Panel A 
represents the percentage of viable cells in each treatment group, and higher 
concentrations of 80 and 120 µM acrolein show a significant decrease in cellular 
viability. With regards to the result from the ViaCount assay, we decided to use acrolein 
concentration of 40 µM and below to perform functional tests relating to cardiovascular 
risk assessment.      
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     Acrolein-Induced Monocyte Binding to Endothelial Cells 
Atherosclerosis and other cardiovascular conditions are dependent on the 
interaction of blood monocytes to inflamed endothelial cells. To examine the effect of 
acrolein on endothelial-monocyte binding, we performed an adhesion assay. EA.hy926 
cells, treated with 10, 20, and 40 µM concentrations of acrolein for 6 hours, were 
incubated with calcein-labeled THP-1 monocytes for an additional hour and fluorescence 
intensity of the bound monocytes was quantified. All investigated concentrations of 
acrolein significantly increased monocyte adherence to EA.hy926 cells (Fig. 2). The 
monocyte binding did not follow a dose-dependent pattern, but all acrolein concentrations 
resulted in an approximate 1.5 fold increase in monocyte adherence compared to an 
untreated control. 
 
     Acrolein-Induced Expression of Adhesion Molecules 
The binding of blood monocytes to endothelial cells are mediated by endothelial 
cell adhesion molecules (ECAMs), and the expression of these surface molecules are 
altered at inflammatory sites. We used qRT-PCR to examine the expression of various 
adhesion molecules and cytokines following acrolein treatment. EA.hy926 cells were 
treated with a single concentration of 20 µM acrolein for 3 hours and mRNA levels of 
monocyte chemoattractant protein-1 (MCP-1), E-selectin, and Interleukin 8 (IL-8) were 
determined. The acrolein treatment significantly increased the relative mRNA levels of 
all three molecules. Approximate increases of 2, 6, and 4.5 fold were observed for MCP-
1, E-selectin, and IL-8 respectively (Fig. 3A, 3B, 3C).  
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     Acrolein Increased ROS Levels in EA.hy926 Cells  
Increased ROS levels has been implicated in the pathogenesis of cardiovascular 
and other diseases as well. Here, we wanted to examine if acrolein can induce ROS levels 
using the luminol-ROS-chemiluminescence assay. Luminol derived chemiluminescence 
(CL) assay is a highly sensitive method with a comparatively low detection limit. It has 
been used widely in the detection of ROS, primarily hydrogen peroxide (H2O2). 
EA.hy926 cells were treated with a single concentration of 10 µM acrolein and ROS 
levels were determined concurrently by measuring the integrated chemiluminescence for 
30 minutes at 24 second intervals. Acrolein, at 10 µM concentrations, significantly 
increased ROS levels in endothelial cells. It resulted in a 2 fold increase in ROS levels in 
EA.hy926 cells (Fig. 4).  
 
     Acrolein Depleted Cellular and Mitochondrial GSH 
Glutathione (GSH), specifically mitochondrial GSH, is a key cellular antioxidant 
that aids in the maintenance of exogenously or endogenously produced ROS. Changes in 
GSH levels directly correspond to intracellular oxidative imbalance. With regards to the 
previous finding of increased ROS levels following acrolein treatment, we sought to 
examine intracellular GSH levels following acrolein exposure. EA.hy926 cells were 
treated with 10, 20, and 40 µM concentrations of acrolein and total cellular, as well as 
mitochondrial, GSH levels were determined. Compared to an untreated control, both 
intracellular and mitochondrial GSH decreased in a dose-dependent manner (Fig. 5A, 
5B). Although significant, the mitochondrial GSH did not exhibit a similar depleting 
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response as the intracellular GSH indicating that prolonged exposure to acrolein may be 
required to deplete mitochondrial GSH to extremely low levels. 
 
     Acrolein-Induced Nf-kB Activation 
The Nf-kB transcription factor is activated in various disease states, and it has 
also been recognized to mediate the expression of adhesion molecules and chemokines 
during atherosclerotic progression [11, 43]. Here, we used western blotting and 
transfection assay to determine Nf-kB activation by acrolein in endothelial cells. Western 
blot analysis showed a significant increase in the protein levels of p65 in the nuclear 
lysate of EA.hy926 cells, treated with 40 µM acrolein (Fig. 6A). Over time, there was 
further translocation of the p65 subunit from the cytosol to the nucleus. In accordance 
with p65 translocation, the protein levels of inhibitor of kappa B (IkB-α) decreased over 
time with acrolein treatment (Fig. 6B). Furthermore, acrolein also significantly increased 
the transcriptional activity of Nf-kB over time, as illustrated by an increased luciferase 
activity for the Nf-kB-reporter plasmid (Fig. 6C). It indicates acrolein increases the 
expression of Nf-kB-regulated genes.    
 
Discussion 
 There is strong epidemiological evidence linking air pollution exposure with 
increased risk of developing CVDs [12, 13, 21]. However, specific chemicals and 
toxicants, within the air pollution mixture, that contributes significantly towards 
increased CVD risk have not been identified and studied in detail. In this study, we 
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examined the early atherogenic impact posed by acrolein, an α, β-unsaturated aldehyde 
predominantly found in air pollution. Early atherogenesis is a progressively inflammatory 
process initiated through endothelial dysfunction. Damage to the endothelial monolayer, 
through endogenous or exogenous factors, results in loss of its function and is 
characterized by increased permeability, inflammation, expression of adhesion 
molecules, and increased leukocyte interactions [10, 33]. The interaction of activated 
endothelial cells with blood monocytes is a hallmark of early atherosclerotic development 
and has been tested extensively in animal and cellular models. Pro-atherogenic factors 
like ox-LDL, hypertriglyceridemia, TNF-α, angiotensin II have all been reported to 
increase monocyte recruitment to endothelial cells in vitro [11, 34-36, 44]. Similarly, 
TNF-α and hypercholesterolemia have also been reported to increase leukocyte 
interactions to the aortic endothelium in mice [45, 46].Our study was designed to 
examine the effect of acrolein on monocyte-endothelial interaction by adhesion assay. 
And we demonstrated that acrolein, at non-lethal concentrations, significantly increased 
the binding of THP-1 monocytes to EA.hy926 endothelial cells. The results provide 
evidence for the cardiovascular risk of acrolein exposure.    
 We further sought to understand the mechanisms underlying acrolein-induced 
monocyte-endothelial binding, and investigated the involvement of adhesion molecules 
and chemotactic cytokines aiding the adhesion process. It has been well-documented that 
the binding of monocytes are facilitated by adhesion molecules and cytokines expressed 
by activated endothelial cells [3, 32]. Molecules like ICAM-1, VCAM-1, E-selectin, P-
selectin, MCP-1, IL-8 have been understood to play a key role in monocyte-endothelial 
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interactions, and increased levels of these molecules have also been reported in patients 
with atherosclerosis and CVDs [10, 37]. In this study, we used qRT-PCR to measure the 
expression of adhesion molecules and found that acrolein treatment significantly 
increased the mRNA levels of MCP-1, E-selectin, and IL-8.  
 Several studies have indicated that reactive oxygen species (ROS) can regulate 
the expression of adhesion molecules. Increased ROS production in endothelial cells has 
been implicated to induce inflammatory mediators like tumor necrosis factor-alpha (TNF-
α), interleukins, VCAM-1, ICAM-1, and P-selectin and subsequently result in endothelial 
activation and dysfunction [47, 48]. Reactive oxygen species (ROS) are highly reactive 
and can interact with cellular macromolecules abolishing their functions [49]. In the case 
of endothelial cells, the loss of function correlates with loss of the anti-inflammatory, 
anti-coagulant, and impermeability properties making them susceptible for atherogenesis 
[4]. Changes in the vascular environment and function by oxidants have been understood 
to accelerate atherosclerotic development [50]. In addition to cellular injury, ROS can 
alter low-density lipoproteins (LDL) [51]. Oxidation of LDL is also an early step in 
atherosclerotic development, and Ox-LDL has been studied extensively to be considered 
as a pro-atherogenic risk factor [35, 51]. In this study, we showed that acrolein can 
significantly increase ROS levels at low concentrations in endothelial cells, suggesting 
that acrolein-induced expression of cell surface adhesion molecules might be regulated 
by ROS. 
 Although we demonstrate that acrolein can increase cellular ROS, the mechanism 
through which ROS are produced remains unclear. ROS can be generated through 
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multiple mechanisms in cells. First, NADPH oxidase is well known to function as a 
generator of superoxide, especially in leukocytes [52]. It is a membrane-bound enzyme 
complex that transfers electron from NADPH to molecular oxygen and produces the 
superoxide anion [48]. ROS produced from activated NADPH oxidase has also been 
studied in the pathogenesis of atherosclerosis [48]. The increase in ROS observed in this 
study might be through acrolein-triggered NADPH oxidase activity. Second, the 
mitochondrial electron transport chain is also an active site for the production of ROS. 
Leakage of electrons at mitochondrial complex I and complex III has been associated 
with the production of superoxide [53, 54]. In addition, studies have also demonstrated 
that disruption of the electron transport chain through mitochondrial damage or blockage 
of the respiratory complexes can significantly increase ROS production [54]. Acrolein, 
might also inhibit the mitochondrial electron transport chain to increase ROS production. 
Finally, low levels of cellular antioxidants have also been implemented to directly 
increase ROS production [55]. Cellular antioxidants serve as targets for ROS and protect 
cellular macromolecules by nullifying the effect of ROS. Acrolein is a highly 
electrophilic molecule and it may directly react with cellular nucleophiles and 
antioxidants to increase the cells susceptibility to ROS.     
GSH is an intracellular tripeptide antioxidant that reacts with ROS and makes 
them inactive; it is a key molecule essential in maintaining redox homeostasis and 
protecting cells from oxidative stress [56, 57]. In correspondence with our finding of 
acrolein-induced ROS levels in endothelial cells, we also examined the effect of acrolein 
on cellular GSH levels. Acrolein significantly depleted cellular GSH levels, which 
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correlates with increased ROS production. In addition, we also found that acrolein 
significantly decreased mitochondrial GSH. Mitochondria are not only involved in the 
production of ROS from the electron transport chain, but they also serve as a site for 
damage from ROS, further generating additional ROS. It is well-established that 
mitochondria have a separate pool of GSH that defends against ROS produced actively 
during the electron transport chain [55]. In addition, mitochondrial ROS has also been 
shown to enhance TNF-α-induced expression of E-selectin and VCAM-1 expression [55]. 
Altogether, these findings suggest that acrolein may have increased ROS levels in 
endothelial cells by decreasing cellular and mitochondrial GSH, which eventually, may 
modulate the expression of adhesion molecules and chemokines in endothelial cells. 
Acknowledging the uncertainty in the mechanism behind acrolein-influenced ROS 
production, future work could examine the two other mechanisms stated earlier: acrolein-
induced activation of NADPH oxidase and acrolein-induced mitochondrial 
dysfuntion/disruption of the electron transport chain. Future work could also investigate 
whether induction of intracellular GSH would lead to decreased acrolein-mediated ROS 
production. 
Nuclear factor kappa B (Nf-kB) transcription factor has been implicated in 
various inflammation-related disease conditions, including atherosclerosis. It regulates 
the expression of various genes involved in stress, inflammation, proliferation, and 
apoptosis [58]. Studies have reported that the expression of adhesion molecules involved 
in monocyte-endothelial interactions are upregulated with Nf-kB activation [11, 43]. In 
the cytoplasm under normal conditions, Nf-kB is associated with inhibitor of kappa B 
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(IkB-α). Under the influence of various stimuli, phosphorylation and subsequent 
degradation of IkB-α releases the Nf-kB p65 subunit, which translocates into the nucleus. 
The p65 subunit acts as a transcription factor and enhances the expression of 
proinflammatory mediators, cytokines, and adhesion molecules [58]. Studies have shown 
that induction of adhesion molecule and cytokine expression by TNF-α is regulated by 
Nf-kB activation [11, 59]. So as to understand the signaling pathway involved in 
expression of adhesion molecules and cytokines, we examined whether acrolein could 
also activate Nf-kB signaling. Western blot analysis showed that acrolein increased the 
nuclear abundance of the p65 subunit in endothelial cells in a time-dependent fashion. In 
accordance with the nuclear translocation, acrolein also resulted in degredation of IkB-α 
in the cytoplasm in a time-dependent manner. We also transfected EA.hy926 cells with 
Nf-kB promoter containing luciferase vector and observed that the transcriptional activity 
of the Nf-kB promoter was also significantly increased with acrolein treatment. These 
results provide concrete evidence for the involvement of the Nf-kB pathway and suggest 
that acrolein-induced expression of adhesion molecules may be modulated by this 
signaling pathway. To further specify a causal relationship between acrolein-induced 
expression of adhesion molecules and Nf-kB activation, future studies could also 
investigate whether chemical inhibition or siRNA knockdown of Nf-kB could ameliorate 
acrolein-induced inflammation in endothelial cells.   
In summary, this study assesses the risk of acrolein towards endothelial 
dysfunction. Acrolein significantly decreased cellular and mitochondrial GSH and 
increased production of ROS. Several studies have reported that ROS can activate the Nf-
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kB pathway [58, 60]. In that regard, acrolein also activated the Nf-kB pathway which 
corresponds to increased expression of adhesion molecules and cytokines and increased 
monocyte adherence to endothelial cells. Therefore, we postulate that induction of 
oxidative stress through GSH depletion by acrolein modulates Nf-kB-regulated 
expression of adhesion molecules and cytokines in endothelial cells (Fig. 7). These 
findings add to our understanding of the mechanisms involved in acrolein-induced 
endothelial dysfunction.
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CHAPTER III 
IMPORTANCE OF GSH IN ACROLEIN-INDUCED CELL DEATH 
 
 
Abstract 
 Acrolein, a reactive aldehyde species, gets released into the atmosphere through 
incomplete combustion of organic matter and burning of fuels. High levels of acrolein are 
found in cigarette smoke, which is a primary route of human exposure. This study 
examines the mechanism behind acrolein-induced endothelial cell death and the effects of 
modulating intracellular antioxidant levels against acrolein cytotoxicity. Since endothelial 
cell death has been shown to increase the risk of developing atherosclerotic lesions at 
those sites, understanding the mechanism of acrolein-induced cytotoxicity could provide 
novel targets for cardiovascular therapies. Acrolein, at 80 and 120 µM concentration, 
significantly induced necrotic cell death as evidenced by the increased release of LDH 
and PI staining. It also resulted in a significant depletion of the cellular antioxidant, GSH. 
We dwelled further into the role of GSH in acrolein-induced endothelial cell death by 
using BSO, an inhibitor of the cellular GSH biosynthesis pathway, and found that BSO 
pretreatment significantly reduced cellular viability. Acrolein concentration, as low as 10 
µM, demonstrated significant decrease in viability for the BSO pretreated group. To 
further understand the role of GSH in acrolein cytotoxicity, CDDO-Im was used to 
upregulate cellular GSH levels. Pretreatment of EA.hy926 cells with CDDO-Im, prior to 
acrolein exposure, significantly increased viability through activation of the Nrf2
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signaling pathway. The results from this study may contribute towards the assessment of 
cardiovascular risk of human exposure to acrolein and signifies the importance of GSH 
and Nrf2 signaling in the process.  
  
Introduction 
Cardiovascular diseases (CVDs) account for the highest mortality rates in both, 
men and women, in the United States and across the world as well. Atherosclerosis, a 
pathological condition that precedes most CVDs, involves the narrowing and hardening 
of the arteries through extensive buildup of plaques in the arterial walls [10]. Endothelial 
cell injury is crucial towards the pathogenesis of atherosclerosis. In addition to 
functioning as a blood barrier, endothelial cells regulate vascular homeostasis, platelet 
activity, leukocyte adhesion, permeability, and innate immunity [4]. Any damage to the 
endothelium, sustained through the body’s immune response, infection, or other factors, 
would affect its normal functioning and has been suggested to be a starting point for 
atherosclerotic development [61, 62]. A high turnover rate of these endothelial cells, 
including increased cell death and cell proliferation, has been identified as one of the 
important factors contributing towards atherosclerotic development [61]. The increased 
turnover rate affects the integrity of the vascular endothelium, exhausts its anti-
inflammatory properties, and makes them susceptible towards thrombosis and 
atherosclerotic plaque development [62, 63]. In addition, characterizing the type of cell 
death is also essential as variable endpoints can be achieved through each type. 
Endothelial cell apoptosis has also been studied in the pathophysiology of 
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atherosclerosis; pro-atherogenic risk factors, such as hyperglycemia, oxidized low density 
lipoprotein (ox-LDL), and angiotensin II, have all been shown to induce apoptosis in 
endothelial cells [62, 64]. However, apoptotic cells are cleared up by macrophages 
limiting the damage from spreading to surrounding tissues. In contrast, necrotic cell death 
involves the rupture of the plasma membrane and release of intracellular components 
which can amplify the inflammatory response in the surrounding tissues exacerbating the 
injury [65].       
Epidemiological studies have demonstrated association between exposure to air 
pollution and the risk of developing CVDs [12, 13]. Studies have shown that diesel 
exhaust particles caused damage and affected viability in human pulmonary artery 
endothelial cells [66]. In addition, cigarette smoke condensate at a concentration of 100 
µM has been reported to induce necrosis in endothelial cells [67]. However, specific 
chemicals, within cigarette smoke, that incur such pathological effects have not been 
identified. Acrolein, a highly reactive aldehyde species, is a major air pollutant and a 
component of cigarette smoke as well. Fujioka and Shibamoto (2006) have reported 
about 200-500 µg of acrolein in a single cigarette [26]. Acrolein has been found to induce 
lung cell death via inflammation and increased oxidative stress [68]. It has also been 
shown to induce apoptosis in human bronchial epithelial cells through increased 
generation of cellular oxidants, and modulation of cellular antioxidants ameliorated 
acrolein cytotoxicity [42]. Since the primary route of human exposure to acrolein is 
through inhalation, acrolein has been studied in the pathogenesis of various respiratory 
diseases. However, acrolein-induced endothelial cell death and subsequent cytoprotection 
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against this damage has not been studied extensively. Such studies would provide an 
insight towards the cardiovascular risk implications of acrolein exposure, and it could 
also assist with the identification of therapeutic targets that aid the restoration of a 
healthy, functional endothelium. 
This study examined the cytotoxic mechanisms of acrolein on EA.hy926 
endothelial cells. We hypothesized that depletion of GSH will potentiate acrolein-
mediated cytotoxicity and augmentation of intracellular GSH will ameliorate acrolein 
toxicity in endothelial cells. We demonstrated that acrolein significantly induced necrotic 
cell death at higher concentrations and depleted cellular GSH levels. Furthermore, 
induction of GSH via the Nrf2 signaling pathway by CDDO-Im afforded cytoprotection 
against acrolein toxicity in endothelial cells.    
 
Materials and Methods 
 
     Chemicals 
Acrolein (≥95%, GC) was from Sigma chemicals (St. Louis, MO). Dulbecco’s 
Modified Eagle Medium (DMEM), Fetal Bovine Serum (FBS) and Penicillin 
Streptomycin (Penn Strep) were from Gibco-Invitrogen (Carlsbad, CA). Annexin V dye 
and SYBR® Green Master Mix were from Life Technologies (Grand Island, NY). 
Oligonucleotide primers were from Eurofins (Huntsville, AL).  TGX™ precast gels and 
western blot buffers were from Bio-Rad (Hercules, CA). Nrf2 and GAPDH primary 
antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA) and Cell Signaling 
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Technology Inc. (Danvers, MA) respectively. The FuGENE® HD Transfection Reagent 
and Dual-Glo® Luciferase Assay System were from Promega (Madison, WI). All other 
general chemicals were from Sigma-Aldrich (St. Louis, MO).  
 
     Cell Culture and Treatment 
 EA.hy926 endothelial cells were grown in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 1% Penicillin 
Streptomycin (Penn Strep) in cell culture treated flasks at 37°C with 5% CO2 in a 
humidified incubator. The culture media was replaced every 2-3 days and cells were 
passaged around 90% confluence. For acrolein treatment, the cells were grown in cell 
culture treated petri-dishes under the same conditions. Acrolein was diluted in Medium 
199 (M199) supplemented with 2% FBS and 1% Penn Strep. The DMEM media was 
replaced with the acrolein-diluted M199 media and incubated for different time periods 
based on the specific assays.   
 
     MTT Assay  
EA.hy926 cells were grown to about 80% confluence in 96-well tissue culture 
plate. Following incubation of the cells with different concentrations of acrolein for 24 
hours, the media was replaced with 0.5% FBS supplemented DMEM containing 
0.2mg/ml MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) reagent 
and the cells were further incubated for 3 hours. A mixture of dimethyl sulfoxide, 
isopropanol, and deionized water (1:4:5) was added and cells were incubated at room 
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temperature for 20 minutes in a rotating platform shaker. Finally, the amount of dissolved 
formazan was quantified by measuring absorbance at 570 nm using the Bio-Tek 
microplate reader to determine cell viability. 
 
     Lactose Dehydrogenase (LDH) Assay  
EA.hy926 cells were grown to confluence, followed by acrolein exposure for 24 
hours. Treatment media was collected and centrifuged for 5 minutes at 13,000 rcf. The 
collected supernatant was mixed with pyruvate and NADH and enzymatic activity of the 
LDH released in the media was determined by measuring absorbance at 320 nm.  
 
     Apoptosis/Necrosis Assay 
Apoptosis/necrosis was detected with the Invitrogen Dead cell Apoptosis kit 
following the manufacturer’s protocol. EA.hy926 cells were grown to confluence and 
treated with acrolein for 24 hours. The cells were harvested through trypsinization and 
washed once with PBS. The cells were stained with Annexin V-FITC and Propidium 
iodide (PI) in 1X binding buffer and fluorescence was analyzed by excitation at 488 nm 
and emission at 530 nm in the Guava easyCyte flow cytometer.   
 
     Sample Preparation 
After acrolein treatment, the treatment media was dumped and the cells were 
washed with Phosphate Buffered Saline (PBS) twice. The cells were trypsinized with the 
addition of about 4 mL of trypsin, followed by incubation at 37°C for 3 minutes and 
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collected through centrifugation. The pellet was resuspended in PBS to wash off trypsin 
and media remnants. The cells were centrifuged again and the pellet was resuspended in 
250 µL of sterile tissue lysis buffer. Next, the cells were sonicated 3 times for 15 seconds 
with a 15 second interval after each sonication. The sonicated cell lysate was centrifuged 
again and the supernatant was collected in a new microcentrifuge tube and was used to 
perform the various antioxidant enzyme assays.  
 
     Total Protein Assay  
Ten µL of the sample was diluted in 790 µL of deionized water and 200 µL of 
Bradford Protein Dye was added to bring the final volume to 1 ml. The solution was 
mixed thoroughly and sample absorbance at 595 nm was measured to determine the total 
protein concentration based on the absorbance of a Bovine Serum Albumin (BSA) 
standard, 1.48 mg/ml. 
 
     Glutathione (GSH) Assay  
EA.hy926 cells were grown to confluence, followed by acrolein exposure for 24 
hours. The cell lysate was incubated with meta-phosphoric acid and 0.1% sodium 
phosphate buffer at pH 8.0 for 10 minutes. The sample was centrifuged at 13,000 rpm for 
5 minutes, and the resulting supernatant was further incubated with o-phthalaldehyde 
(OPT) solution and 0.1% sodium phosphate buffer for 15 minutes. Fluorescence intensity 
of GSH-OPT was measured by excitation at 350 nm and emission at 420 nm. The sample 
34 
 
GSH content was calculated using a GSH standard curve and expressed as percent 
change to an untreated control. 
 
     Glutathione S-Transferase (GST) Assay  
EA.hy926 cells were grown to confluence, followed by acrolein exposure for 24 
hours. Fifteen µl of the collected cell lysate was mixed with Tris-HCl buffer at pH 7.5, 
1% BSA, 1-Chloro-2,4-dinitrobenzene (CDNB), and 100 mM GSH. GST catalyzes the 
conjugation of GSH to CDNB, with the product having a strong absorbance at 340 nm. 
The enzyme activity was determined by following the absorption of the GSH-CDNB 
conjugate at 340 nm.   
 
     NADPH Quinone Oxireductase-1 (NQO1) Assay  
EA.hy926 cells were grown to confluence, followed by acrolein exposure for 24 
hours. The cell lysate was mixed with Tris-HCl buffer at pH 7.5, NADPH, and 
Dichlorophenolindophenol (DCPIP). The enzyme activity was determined by following 
the continuous reduction of DCPIP which leads to decreased absorbance at 600 nm.  
 
     Nuclear Extract Preparation  
Once treated with acrolein, the cells were collected through trypsinization and 
nuclear proteins were isolated using the EpiQuik Nuclear Extraction Kit as per the 
manufacturer’s protocol.    
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     Western Blot  
Following 100 nM CDDO-Im treatment, the nuclear extract from EA.hy926 cells 
was diluted in Laemmli buffer containing β-mercaptoethanol, heated at 95°C for 5 
minutes, and loaded into TGX™ precast gels. After running the gels, the separated 
proteins were transferred to a nitrocellulose membrane. The membrane was blotted in 1% 
BSA for an hour and washed off. The blotted membrane was probed with anti-Nrf2 
primary antibodies overnight at 4°C. The membrane was then probed with horseradish 
peroxidase-conjugated secondary antibody for an hour. The blot was then incubated with 
the Super Signal West Pico Chemiluminescent Substrate for 5 minutes and protein bands 
were developed under the Bio-Rad ChemiDoc XRS System. The membrane was 
incubated in stripping buffer to strip off bound antibodies, washed with Tris-Buffered 
Saline containing Tween 20 (TBST), and blotted in 1% BSA. The membrane was probed 
again with anti-GAPDH primary antibodies, and protein levels of GAPDH were used as 
loading control.   
 
     Transfection Assay 
EA.hy926 cells, grown to about 60% confluence, were transfected with Firefly 
luciferase containing plasmid vectors and Renilla luciferase reporter vector using the 
FuGENE® HD Transfection Reagent in accordance with the manufacturer’s protocol. 
Following transfection, the cells were treated with 100 nM CDDO-Im for 6 hours in 
presence of the transfection media. The transfected cells were washed with PBS and then 
lysed in a reporter lysis buffer. Firefly luminescence and renilla luminescence were 
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measured in a luminometer using the Dual-Glo® Luciferase Assay System in accordance 
with the provided protocols and as previously described [11]. The renilla luminescence 
served as a control and was used to normalize the expression of other target vectors.  
 
     Quantitative Polymerase Chain Reaction (qRT-PCR)  
EA.hy926 cells were grown to confluence and exposed to acrolein for 6 hours. 
Total RNA from the cells was extracted using the Trizol Reagent. The purity and quantity 
of the isolated RNA were assessed using the Nanodrop spectrophotometer. The isolated 
RNA was then reverse transcribed to cDNA. One µl of the amplified cDNA was added to 
the SYBR® Green real-time PCR master mix along with primer sets specific to Nrf2, 
GCLC, GCLM, NQO1, and HO. The specific primers for Nrf2 were forward 5'-
GCGACGGAAAGAGTATGAGC-3' and reverse 5'-GTTGGCAGATCCACTGGTTT-3', 
GCLC were forward 5'-ACCATCATCAATGGGAAGGA-3' and reverse 5'-
GCGATAAACTCCCTCATCCA-3', GCLM were forward 5'-
CTCCCTCTCGGGTCTCTCTC-3' and reverse 5'-ATCATGAAGCTCCTCGCTGT-3', 
NQO1 were forward 5'-TTACTATGGGATGGGGTCCA-3' and reverse 5'-
TCTCCCATTTTTCAGGCAAC-3', HO were forward 5'-
TCCGATGGGTCCTTACACTC-3' and reverse 5'-TAAGGAAGCCAGCCAAGAGA-3' 
and GAPDH were forward 5'-CGACCACTTTGTCAAGCTCA-3' and reverse 5'-
AGGGGTCTACATGGCAACTG-3'. The reaction cycles was performed in the Applied 
Biosystems thermal cycler. A total of 40 cycles were performed for each run as follows: 
95ºC for 15 seconds, 61ºC for 30 seconds, and 72ºC for 30 seconds. Expression of the 
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housekeeping gene, GAPDH, was also acquired to normalize the expression of other 
target genes. Quantification of gene expression was determined using the comparative 
threshold cycle CT method and expressed as fold-change compared to the untreated 
control. 
 
Results 
 
     Acrolein-Induced Endothelial Cell Death 
To further confirm acrolein-mediated cell death, we performed the MTT and LDH 
assay. EA.hy926 cells were treated with 20, 40, 80, and 120 µM concentrations of 
acrolein for 24 hours and the two aforementioned viability assays were performed to 
examine acrolein-induced cell death. EA.hy926 cells, treated with acrolein at higher 
concentrations of 80 µM and 120 µM, showed a significant decrease in cell viability, 
while lower concentrations of 20 µM and 40 µM did not decrease cell viability. Acrolein 
at 80 µM and 120 µM significantly increased the release of cellular LDH in the culture 
media, as detected by the LDH assay (Fig. 8B). The MTT assay also confirmed a 
decrease in cellular viability at those concentrations (Fig. 8A). 
 
     Acrolein Promoted Necrosis in EA.hy926 Cells 
The induction of apoptosis/necrosis following acrolein treatment was analyzed by 
flow cytometric analysis of EA.hy926 cells stained with Annexin V-FITC and PI. 
Externally translocated phosphotidylserine in apoptotic cells are stained with Annexin V-
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FITC while PI enters necrotic cells and binds to DNA. Figure 2A represents double 
staining plots with Annexin V and PI. The lower left quadrant (Annexin - /PI -) 
represents viable cell population. The lower right quadrant (Annexin +/PI -) represents 
apoptotic cell population. The upper right (Annexin +/PI +) and the upper left (Annexin -
/PI +) quadrants represent necrotic cell populations. Acrolein treatments significantly 
increased cell population at the upper two quadrants indicating that acrolein promotes 
necrosis in endothelial cells. Acrolein treatment of 80 µM and 120 µM significantly 
increased the number of necrotic cells indicated by the high percentage of cells stained by 
PI (Fig. 9B).With regards to such finding, we decided to use concentrations of 80 µM and 
above to perform our mechanistic studies.   
 
     Acrolein Depleted Cellular GSH, GST, and NQO1 
  Glutathione (GSH) is an important cellular antioxidant in animal cells that 
protects them against oxidative damage from reactive oxygen species (ROS) and free 
radicals. GST and NQO1 are enzymes that are involved in cellular biotransformation so 
as to assist with the detoxification and excretion of xenobiotics and endobiotics. The 
effect of acrolein on GSH, GST, and NQO1 levels were examined using OPT-GSH 
fluorescence and enzyme kinetic assays respectively. EA.hy926 cells significantly 
decreased cellular GSH at both acrolein concentrations in a dose-dependent manner (Fig. 
10A). Similarly, acrolein also significantly decreased cellular glutathione-S-transferase 
(GST) and NAD(P)H:quinone oxidoreductase type1 (NQO1) in EA.hy926 cells (Fig. 
10B, 10C). 
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     GSH-Dependent Acrolein Toxicity 
To determine if acrolein toxicity in EA.hy926 cells was dependent on cellular 
GSH, we pre-treated the cells with buthionine sulfoximine (BSO) followed by acrolein 
treatment. BSO inhibits γ-glutamylcysteine ligase, the fundamental enzyme in cellular 
GSH biosynthesis pathway. First, working concentrations of BSO were tested for toxicity 
in EA.hy926 cells with a ViaCount assay. Cells, treated with 25 µM and 50 µM 
concentrations of BSO for 24 hours, did not show a difference in cellular viability, when 
compared to an untreated control (Fig. 11A). Next, the functionality of BSO to inhibit 
cellular GSH synthesis was tested. EA.hy926 cells were treated with 25 µM and 50 µM 
concentrations of BSO for 24 hours and cellular GSH was measured. Figure 11B shows 
that both 25 µM and 50 µM concentrations of BSO significantly decreased cellular GSH. 
Hereafter, all other experiments with BSO included a single concentration of 25 µM.     
To examine whether acrolein toxicity was dependent on GSH, a MTT assay was 
performed to measure acrolein-induced cell death with or without BSO pretreatment. 
Cells were pretreated with or without BSO for 24 hours, followed by various 
concentrations of acrolein in fresh media for another 24 hours. Comparing cellular 
viability at each individual concentrations of acrolein, the BSO pretreated group had 
significantly less viable cells than the BSO untreated group (Fig. 11C). In the BSO 
untreated group, significant decrease in cellular viability was only observed at a higher 
concentration of 80 µM acrolein, consistent with previous results. However in the BSO 
pretreated group, significant decrease in cellular viability was observed in concentrations 
as low as 10 µM acrolein.    
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     Upregulation of Antioxidant Defense by CDDO-Im Protects against 
     Acrolein-Induced Cell Death 
Next, we examined the modulatory effects of elevated GSH levels on acrolein 
cytotoxicity. CDDO-Im, 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazoleis, 
is a synthetic triterpenoid based of naturally occurring oleanolic acids. It has been found 
to possess anti-inflammatory and antioxidant properties and has been studied extensively 
as a treatment strategy against cancer [69]. CDDO-Im has been reported to induce 
cytoprotective genes and protect hepatocytes against aflatoxin-induced tumorigenesis 
[70]. However, there seems to be a gap in studies examining the cytoprotective 
capabilities of CDDO-Im on endothelial cell death. We first examined the potential of 
CDDO-Im to induce antioxidant GSH and phase II detoxification enzymes, NQO1 and 
GST. All tested concentrations of CDDO-Im increased cellular levels of GSH in a near 
dose-dependent manner (Fig 12A). CDDO-Im at 100 nM increased cellular GSH by over 
1.5 fold. Similarly, CDDO-Im also induced cellular levels of NQO1 in a dose-dependent 
manner, and the concentration of 100 nM resulted in a 1.5 fold increase in NQO1 (Fig 
12B). Cellular GST levels were not altered by CDDO-Im.  
To further study whether upregulated levels of GSH and antioxidant defense by 
CDDO-Im can protect cells against acrolein-induced cell death, we pretreated EA.hy926 
cells with 100 nM CDDO-Im for 24 hours followed by acrolein treatment in fresh media 
and cellular viability was measured using the MTT assay and the ViaCount assay. 
Comparing cellular viability at each individual concentrations of acrolein, the CDDO-Im 
pretreated group had significantly more viable cells than the CDDO-Im untreated group 
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(Fig. 13A). Although both groups, with and without CDDO-Im, exhibited a dose-
dependent response to acrolein treatment, the CDDO-Im treated group had significantly 
higher percent of viable cells at each acrolein concentration. The ViaCount assay also led 
to similar conclusions (Fig. 13B, 13C); acrolein treatment of 80 µM and 120 µM resulted 
in a 30% and 45% reduction in endothelial cell viability respectively. However with 
CDDO-Im pretreatment, cell viability was only reduced by 10% and 20% for the 
aforementioned concentrations of acrolein. The phase contrast pictures taken under the 
EVOS xl microscope also showed drastic changes in cell morphology and increased 
number of dead, floating cells following acrolein treatment in the CDDO-Im untreated 
group (Fig. 14).    
 
     CDDO-Im Mediated Nrf2 Signaling 
Activation of nuclear factor-erythroid 2-related factor 2 (Nrf2) has been reported 
to coordinately upregulate GSH and phase II enzymes in vitro [71]. Nrf2, in the 
cytoplasm, is bound to Keap1 protein. Upon release from Keap1, in response to various 
stimuli, Nrf2 translocates to the nucleus and binds to antioxidant response element (ARE) 
in the promoter region of antioxidant genes stimulating their expression. To understand 
the mechanism behind CDDO-Im-induced GSH and antioxidant defense levels, we first 
looked into CDDO-Im-induced nuclear translocation of Nrf2 in EA.hy926 cells.  Western 
blot analysis showed increased Nrf2 levels in the nucleus of CDDO-Im treated cells in a 
time-dependent fashion (Fig. 15A). Then, we looked into Nrf2-ARE binding that 
enhances cellular antioxidant gene expression. Firefly luciferase plasmid vectors with 
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ARE inserted in the promoter were transfected into EA.hy926 cells and ARE activity was 
determined through detection of luminescence intensity. It was observed that 
transcriptional activity of luciferase increased with both concentrations of CDDO-Im 
(Fig. 15B), confirming that CDDO-Im stimulates the expression of genes preceded by an 
ARE promoter. Finally, gene expression of Nrf2, GCLC, GCLM, NQO1, and HO was 
quantified by qRT-PCR. Nrf2 had slightly increased expression (Fig. 16A), GCLM had a 
3-fold increase (Fig. 16C), NQO1 had a 7000-fold increase (Fig. 16D), and HO had a 4-
fold increase (Fig. 16E) following CDDO-Im treatment. GCLC did not show a significant 
increase in expression compared to the untreated control (Fig. 16B).  
     
Discussion 
The endothelium plays an important role in regulating vascular homeostasis, and 
any damage or dysfunction of the endothelium represents early stages of atherogenesis 
[4]. Endothelial dysfunction, characterized by inflammation and accumulation of lipids 
and leukocytes in the arterial intima, is the hallmark of early atherosclerosis [4, 10, 11]. 
When endothelial cells become damaged and subsequently die, it decreases the integrity 
of the endothelial monolayer, increases vascular permeability, and makes the inner 
arteries easily accessible for LDL, cholesterol, and leukocytes circulating in the blood. 
Areas of the vasculature with high endothelial cell turnover, characterized by high 
endothelial cell death and regeneration, have been identified to be highly permeable to 
unesterified cholesterol making those sites susceptible for atherosclerotic development 
[61]. Furthermore, these damaged sites also attract blood platelets, resulting in 
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thrombogenesis and plaque development [61]. In this study, we have demonstrated that 
acrolein, a reactive aldehyde species found in cigarette smoke and air pollution, 
decreased endothelial cell viability at higher concentrations of 80 and 120 µM. 
Furthermore, acrolein promoted necrotic cell death in endothelial cells at the 
aforementioned concentrations as evidenced by the increased release of LDH in the 
culture media and increased number of endothelial cells stained with the DNA-binding 
PI. The type of endothelial cell death is highly relevant in the case of atherosclerosis. 
Since atherosclerotic development is understood to be a chronic inflammatory process, 
necrotic cell death could significantly contribute towards its progression. The lysis of 
endothelial cell membranes, through necrosis, allows for the release of cellular content 
and proinflammatory mediators to the surrounding tissues aggravating the inflammatory 
response and increasing the potential of atherosclerotic development at such sites [65, 
67]. The necrotic cell death promoted by acrolein suggests that it could increase the risk 
of atherogenesis at these damaged sites.    
Oxidative damage has been reported to induce cytotoxicity in numerous cell types 
through various signaling pathways. Oxidative stress is attained due to an imbalance 
between the cellular oxidant and antioxidant levels. GSH is an important antioxidant 
molecule that is essential towards maintaining oxidative balance and regulation of 
cellular metabolic functions including signal transduction, cell proliferation, and 
apoptosis [56]. GSH depletion alters the thiol redox balance [56, 72], and in endothelial 
cells, this could lead to the onset of atherosclerotic development. Wedley et al. (2011) 
demonstrated that GSH knockdown in mice influenced vascular reactivity; it was 
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associated with compromised nitric oxide (NO) levels that are important in maintaining 
vascular tone [73]. Studies have also shown that intracellular GSH regulated TNF-α-
induced expression of adhesion molecules and monocyte aggregation in endothelial cells 
[57]. These findings signify the importance of GSH in cardiovascular risk implications 
and may represent a therapeutic target for the prevention of atherosclerosis and other 
CVDs. We demonstrated that acrolein depletes intracellular GSH in a dose-dependent 
manner. This suggests that GSH might be the first line of cellular defense against acrolein 
toxicity. The exhaustion of the cellular GSH eliminates the cellular defenses and makes 
the cell susceptible to oxidative damage [57].  
To further examine the importance of GSH in acrolein-induced cytotoxicity, we 
pretreated the cells with BSO to deplete cellular GSH. BSO inhibits γ-glutamyl cysteine 
ligase, a crucial rate-limiting enzyme in the cellular GSH biosynthesis pathway. We 
observed significantly increased cell death in BSO-pretreated group for all acrolein 
treatments.  Significant decrease in cell viability was observed at 80 µM for acrolein 
treatment alone, however with BSO pretreatment, cell viability was significantly 
decreased at 10 µM acrolein. This provides evidence that depletion of cellular GSH is a 
crucial focal point in acrolein-induced endothelial cell death. Oxidative balance, 
maintained by antioxidant GSH, is crucial for various cell functions and changes to this 
equilibrium, incurred by acrolein, may affect various signaling pathways ultimately 
affecting cell proliferation and inducing necrosis [40, 57, 74]. Since endothelial cell 
damage and death is associated with early stages of atherosclerotic progression and 
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increased susceptibility towards CVDs, alterations in cellular GSH levels could 
potentially influence the pathogenesis of atherosclerosis and other CVDs. 
In addition to GSH, acrolein also significantly depleted cellular GST and NQO1 
levels, two phase II enzymes involved in the biotransformation and detoxification of 
electrophiles and ROS. In this study, we focused solely on GSH and found staggering 
evidence for its importance in acrolein toxicity in ECs. Future work could examine the 
roles of GST and NQO1 in acrolein-mediated cytotoxicity and their detoxification of 
acrolein. In this context, ethacrynic acid and dicoumarol could be used to inhibit cellular 
GST and NQO1 respectively, in an effort to examine their specific roles in acrolein-
induced endothelial cell death.   
To further assess the important role of GSH in acrolein-induced cell death, we 
examined whether increasing cellular GSH levels could protect endothelial cells against 
acrolein toxicity. To that extent, we used CDDO-Im to induce GSH levels endogenously. 
CDDO-Im is a synthetic triterpenoid, based of oleanolic acids. Oleanolic acids are natural 
steroid-like compounds that exist in food, medicinal herbs, and other plants; they have 
been shown to possess anti-inflammatory, anti-tumorigenic, and anti-hyperlipidemic 
properties [75]. CDDO-Im is a synthetic derivative of the oleanolic acid designed for 
higher potency and effectiveness. In this study, CDDO-Im upregulated cellular levels of 
GSH in a dose-dependent manner. CDDO-Im, at 100 nM concentration, increased GSH 
by 1.5 fold and was used for pre-treatment of endothelial cells to examine cytoprotection 
against acrolein toxicity. We observed significantly increased viable cell count in CDDO-
Im pretreated group. CDDO-Im pretreatment decreased endothelial cell viability by 10% 
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and 20% for acrolein treatments of 80 and 120 µM, which is significantly lower 
compared to the 30% and 45% reduction in viability for acrolein treatment alone. In 
accordance with the results from the BSO experiment, these results highlight the 
importance of GSH in maintaining a functioning endothelial monolayer and its protective 
feature against acrolein toxicity. 
The Nrf2/Keap-1/ARE signaling has been suggested to coordinately regulate 
cellular GSH and other phase II enzymes [76-78]. Nrf2, in the cytoplasm is bound to 
kelch-like ECH-associated protein-1 (Keap1). Upon release from Keap1, Nrf2 
translocates to the nucleus and forms heterodimers with Maf proteins. The complex then 
binds to antioxidant response element (ARE), in the promoter region of cytoprotective 
genes, stimulating their expression [71]. Therefore, we examined whether the action of 
CDDO-Im in endothelial cells followed Nrf2 signaling. We observed an increase in the 
abundance of Nrf2 in the nucleus of endothelial cells with CDDO-Im treatment. It also 
increased the transcriptional activity of the ARE promoter in the Dual Glo luciferase 
assay. We also measured the relative mRNA levels of the catalytic and modifier subunits 
of γ-glutamyl cysteine ligase (GCLC and GCLM), the rate-limiting enzyme in the GSH 
biosynthesis pathway. In addition, we also measured Nrf2, NQO1, and HO levels with 
qRT-PCR. The expression level of Nrf2 itself was slightly increased while expression of 
the modifier subunit of the γ-glutamyl cysteine ligase (GCLM) was significantly 
increased by CDDO-Im. These findings suggest that CDDO-Im upregulates cellular GSH 
levels by increasing the expression of GCLM through Nrf2 signaling. In addition, mRNA 
levels of NQO1 and HO were also upregulated in endothelial cells following CDDO-Im 
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treatment. NQO1 and HO are phase II enzymes that respond to stress and are involved in 
the detoxification process. These results suggest that the cytoprotective feature of CDDO-
Im against acrolein toxicity could be from an overall combined effect of antioxidant 
defense regulated by the Nrf2 signaling pathway while not just GSH alone. However, our 
GSH inhibition studies demonstrated the importance of GSH in acrolein toxicity. 
Therefore, we believe that GSH augmentation by CDDO-Im could be a significant factor 
that contributes towards its protective nature against acrolein-induced endothelial cell 
death. In this study, we did not examine the direct effect of arcolein on the Nrf2/ARE 
signaling pathway. Future work could assess how varying concentrations of acrolein 
affect the nuclear translocation of Nrf2 and transcriptional activity of ARE promoter.   
Our results suggest that Nrf2 signaling pathway by CDDO-Im could be a possible 
therapeutic target against atherosclerosis. Oxidative stress has been implicated in the 
pathogenesis of cardiovascular diseases, and Nrf2 signaling is associated with the 
regulation of the cellular antioxidant defense system and phase II detoxification enzymes. 
Therefore, pharmaceuticals and therapeutics that target and constitutively activate the 
Nrf2 pathway could provide a solution against atherosclerosis and other CVDs. CDDO-
Im, itself, may also be a promising therapeutic agent to protect against atherogenesis 
induced by oxidants, including acrolein. 
In summary, this study provides evidence for the cytotoxic effects of acrolein in 
endothelial cells. Acrolein induces necrotic cell death at higher concentrations which 
corresponds to depleted levels of antioxidant GSH in endothelial cells. Furthermore, 
augmentation of cellular GSH levels via the Nrf2 pathway by CDDO-Im provides 
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marked protection against acrolein-induced endothelial cell death (Fig. 17). These 
findings will contribute to understanding the action of acrolein, which is important in the 
development of strategies for the prevention of acrolein toxicity.
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Figure 1. Acrolein-Induced Endothelial Cell Death. EA.hy926 cells were treated with 
the aforementioned concentrations of acrolein for 24 hours and cell viability was 
measured using the ViaCount assay (B). Panel A compares percent viable cells in each 
treatment groups. Data are mean ± SEM. *P<0.05 compared to control group (n=3).   
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Figure 2. Acrolein-Induced Monocyte Binding to Endothelial Cells. EA.hy926 cells 
were treated with the aforementioned concentrations of acrolein for 6 hours. Following 
treatment, the cells were incubated with fluorescently-labeled THP-1 monocytes for an 
additional hour and adhesion was quantified by measuring the fluorescence intensity of 
the bound monocytes. Data are mean ± SEM. *P<0.05 compared to control group (n=3). 
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Figure 3. Acrolein-Induced Expression of Adhesion Molecules. EA.hy926 cells were 
treated with or without 20 µM acrolein for 3 hours. The mRNA levels of MCP-1 (A), E-
selectin (B), and IL-8 (C) were measured by qRT-PCR and normalized to GAPDH 
expression. Data are mean ± SEM. *P<0.05 compared to control group (n=3). 
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Figure 4. Acrolein-Induced ROS Production in Endothelial Cells. EA.hy926 cells, 
suspended in complete phosphate buffered saline (cPBS), were incubated with the 10 µM 
acrolein, Luminol, and horse-raddish peroxidase (HRP). H2O2 levels were determined by 
measuring the resulting chemiluminescence (CL) of luminol catalyzed by HRP and 
enhanced by ROS in a plate reader for 30 minutes at 24 second intervals. Data are mean 
± SEM. *P<0.05 compared to control group (n=3). 
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Figure 5. Acrolein Decreased Total Cellular and Mitochondrial GSH. EA.hy926 cells 
were treated with various concentrations of acrolein for 24 hours. Total cellular GSH (A) 
and mitochondrial GSH (B) content were measured fluorometrically with OPT. Data are 
mean ± SEM. *P<0.05 compared to control group (n=3). 
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Figure 6. Acrolein-Induced Nf-kB Activation. EA.hy926 cells were treated with 40 µM 
acrolein for 3 and 6 hours. The protein levels of p65 (A) in the nuclear lysate and IkB-α 
(B) in the cytoplasmic lysate were determined by western blotting. GAPDH was used as 
a loading control. EA.hy926 cells, cotransfected with Nf-kB-luciferase reporter vectors 
and Renilla luciferase control vectors, were incubated with 40 µM acrolein. 
Transcriptional activity of Nf-kB was determined by measuring luminescence activity of 
the reporter vector (C). Nf-kB-luminescence was normalized to Renilla control vector 
luminescence. Data are mean ± SEM. *P<0.05 compared to control group (n=3). 
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Figure 7. Diagram of Proposed Acrolein-Induced Monocyte Binding to Endothelial 
Cells. 
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Figure 8. Acrolein-Induced Cytotoxicity in EA.hy926 Endothelial Cells. EA.hy926 cells 
were incubated with various concentrations of acrolein for 24 hours and cell viability 
was determined using the MTT assay (A) and LDH assay (B). Data are mean ± SEM. 
*P<0.05 compared to control group (n=3). 
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Figure 9. Acrolein-Induced Necrosis. EA.hy926 cells were treated with the 
aforementioned concentrations of acrolein for 24 hours. Apoptotic and necrotic cells, 
stained with Annexin V and PI dye respectively, were detected through flow cytometry. 
Panel A represents double staining with Annexin V/PI and panel B compares percentage 
of necrotic cells in each treatment group. Data are mean ± SEM. *P<0.05 compared to 
control group (n=3).  
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Figure 10. Acrolein Decreased Cellular GSH, GST, and NQO1 in Endothelial Cells. 
EA.hy926 cells were treated with various concentrations of acrolein for 24 hours and 
cellular GSH content was measured fluorometrically with OPT (A). GST activity was 
measured by following the absorbance of GSH-CDNB conjugate at 340nm (B). NQO1 
activity was measured by following the continuous reduction of DCPIP at 600nm (C). 
Data are mean ± SEM. *P<0.05 compared to control group (n=3). 
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Figure 11. Acrolein Toxicity in EA.hy926 Cells was Dependent on GSH. EA.hy926 
cells were treated with BSO, a chemical inhibitor for GSH biosynthesis, to examine the 
effect of GSH on acrolein toxicity. Panel A and B depict EA.hy926 cells treated with two 
concentrations of BSO for 24 hours. Cellular viability and total GSH content were 
measured using the ViaCount assay and fluorometric detection with OPT respectively. In 
panel C, EA.hy926 cells were pretreated with or without 25 µM BSO for 24 hours, 
followed by treatment with the indicated concentrations of acrolein for another 24 hours. 
Cell viability was measured using the MTT assay. Data represent mean ± SEM. *P<0.05 
compared to untreated control (n=3). #P<0.05 compared to the BSO untreated group 
within the same acrolein treatment (n=3). 
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Figure 12. CDDO-Im Induced Cellular GSH and NQO1 Levels. EA.hy926 cells were 
treated with the indicated concentrations of CDDO-Im for 24 hours. Total GSH content 
was measured fluorometrically with OPT (A) and NQO1 activity was measured by 
following the continuous reduction of DCPIP at 600nm (B). Data represent mean ± SEM. 
*P<0.05 compared to the control group (n=3).  
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Figure 13. CDDO-Im Protected against Acrolein-Induced Cell Death. EA.hy926 cells 
were pretreated with or without 100nM CDDO-Im for 24 hours, followed by treatment 
with the two mentioned acrolein concentrations for another 24 hours. Cell viability was 
measured with the MTT assay (A) and the ViaCount assay (C). Panel B compares 
percent viable cells within and between acrolein treatment groups from the ViaCount 
assay. Data represent mean ± SEM. *P<0.05 compared to untreated control (n=3). 
#P<0.05 compared to the CDDO-Im untreated group within the same acrolein 
treatment (n=3). 
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Figure 14. CDDO-Im Protection in Endothelial Cells. EA.hy926 cells were treated 
with or without 100 nM CDDO-Im for 24 hours, followed by treatment with the two 
acrolein concentrations for another 24 hours. Following treatment, phase contrast 
images were taken under the EVOS xl microscope.  
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Figure 15. CDDO-Im Mediated Nrf2 Signaling. EA.hy926 cells were treated with 
CDDO-Im and Nrf2 protein levels in the nuclear lysate was determined by western 
blotting (A). GAPDH was used as a loading control. EA.hy926 cells, cotransfected with 
ARE-luciferase vector and Renilla luciferase control vectors, were incubated with 
CDDO-Im and luminescence activity was determined (B). ARE-luminescence was 
normalized to Renilla control vector luminescence. Data represent mean ± SEM. 
*P<0.05 compared to the control group (n=3).   
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Figure 16. CDDO-Im Induced Nrf2-Mediated Gene Expression. EA.hy926 cells were 
treated with 100 nM CDDO-Im for 3 hours and mRNA levels of Nrf2 (A), GCLC (B), 
GCLM (C), NQO1 (D), and HO (E) were determined using qRT-PCR. GAPDH 
expression was used to normalize target gene expressions. Data represent mean ± SEM. 
*P<0.05 compared to the control group (n=3).   
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Figure 17. Diagram of Proposed CDDO-Im Mediated Cytoprotection against Acrolein-
Induced Cell Death. 
 
   
 
      
  
    
       
